Eldrin Lewis, MD
Advanced Heart Failure and Transplant Cardiology · Stanford, CANPI 1144287442
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,827 of the $57,278 with a category attached, or 80.0%. Astrazeneca UK Limited accounts for 66.0% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $30,449, 5.9 times the $5,200 reported in 2020.
Across 43 payments — averaging $1332.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$38K
- Merck$11K
- AstraZeneca$4K
- Amgen$2K
- Akebia Therapeutics Inc$1K
- Medtronic$1K
- plus $533 from 4 others
Across 11 payments — averaging $155,978 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$880K
- Akebia Therapeutics Inc$497K
- AstraZeneca$283K
- Amgen$55K
What the payments were for
- Consulting fees$45,82780%
- Travel & lodging$10,37018%
- Food & beverage$1,0812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 17 | $37,776 |
| Merck | 12 | $10,512 |
| AstraZeneca | 6 | $4,028 |
| Amgen | 1 | $2,200 |
| Akebia Therapeutics Inc | 1 | $1,180 |
| Medtronic | 1 | $1,050 |
| Impulse Dynamics (USA) Inc. | 1 | $178 |
| Novartis | 2 | $162 |
| Philips North America LLC | 1 | $150 |
| Cvrx, Inc. | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$7,376
- FARXIGA$2,685
- Corlanor$2,200
- OPTIMIZER$355
- (5044) MCOT$150
How this compares
$57,278 in reported general payments places this provider in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 61 | $83,519 |
| JardianceEmpagliflozin | 95 | $77,230 |
| EliquisApixaban | 27 | $32,538 |
| Digoxin | 22 | $4,635 |
| Mycophenolic AcidMycophenolate Sodium | 22 | $3,717 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $1,875 |
| Icosapent Ethyl | 13 | $1,791 |
| Mycophenolate Mofetil | 19 | $1,469 |
| Rosuvastatin Calcium | 88 | $1,159 |
| Bumetanide | 23 | $1,077 |
| Tacrolimus | 13 | $864 |
| Losartan Potassium | 76 | $732 |
| Metoprolol Succinate | 45 | $634 |
| Spironolactone | 61 | $483 |
| Carvedilol | 48 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $162 | $83,51961 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Stanford
- Ronald WittelesStanford$251K
- Jeffrey TeutebergStanford$195K
- Kevin AlexanderStanford$125K
- Francois HaddadStanford$23K
- Kiran KhushStanford$15K
- Stephanie HsiaoStanford$12K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.